KoreaMed Synapse

Loading [MathJax]/jax/output/HTML-CSS/fonts/TeX/fontdata.js

Journal List > Korean J Gastroenterol > v.58(2) > 1006847

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Jang: Is Certolizumab Pegol an Effective Longterm Maintenance Treatment for Moderate to Severe Crohn's Disease?

Research Update

Korean J Gastroenterol 2011;58(2):121-123.

Published online: 4 October 2011

DOI: https://doi.org/10.4166/kjg.2011.58.2.121

Is Certolizumab Pegol an Effective Longterm Maintenance Treatment for Moderate to Severe Crohn's Disease?

Byung Ik Jang

Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea

Correspondence to: Byung Ik Jang, Department of Internal Medicine, Yeungnam University College of Medicine, 317-1, Daemyung-dong, Nam-gu, Daegu 705-717, Korea. Tel: +82-53-620-3831, Fax: +82-53-654-8386, E-mail: JBI@MED.YU.AC.KR

Copyright © 2011 Korean Ophthalmological Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Continuous therapy with certolizumab pegol maintains remission of patients with crohn's disease for up to 18 months.

Go to :

References

1. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991; 32:913–917.

2. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337:1029–1035.

3. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359:1541–1549.

4. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132:52–65.

5. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130:323–333.

6. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other an-ti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007; 13:1323–1332.

7. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357:228–238.

8. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357:239–250.

9. Lichtenstein GR, Thomsen OØ, Schreiber S, et al. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol. 2010; 8:600–609.

10. Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, place-bo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology. 2005; 129:807–818.

11. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004; 126:402–413.

12. Vermeire S, Schreiber S, Sandborn WJ, Dubois C, Rutgeerts P. Correlation between the Crohn's disease activity and Harvey- Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol. 2010; 8:357–363.

Go to :

TOOLS

Similar articles